After 25 Years of Investment, Singapore’s Biomedical Ambition Shows Real Progress — but the Breakthrough Moment Still Has Not Arrived

Twenty-five years after Singapore began building its biomedical sector, the country can point to a stronger research base, a sizable manufacturing footprint, and a small but notable list of internationally recognized drug-development successes. Yet the broader ambition — turning biomedical sciences into a major pillar of the economy and a globally prominent innovation hub — remains unfinished. 

The sector has produced milestones such as Vonjo, an oral treatment for bone marrow cancer created by SBio and approved by the United States Food and Drug Administration（FDA） in 2022, but experts interviewed in the source material said commercialization, investor sophistication, and talent outcomes still lag behind the strength of Singapore’s scientific infrastructure. The result is a mixed picture: substantial public investment and visible gains, alongside persistent questions about scale, visibility, and how research can more consistently become viable businesses and widely used treatments.

Built for Discovery, Still Seeking Wider Recognition

Singapore’s biomedical push began in 2000 with the Biomedical Sciences Initiative, led by agencies including the Economic Development Board（EDB）, the Agency for Science, Technology and Research（A*STAR）, and JTC Corporation. The effort focused on building human, intellectual, and industrial capital for a new sector that policymakers hoped would eventually become the economy’s fourth pillar. 

A major landmark came in 2003 with the emergence of Biopolis, designed as a research-and-development hub where public and private players could work side by side. Over the years, the government invested billions of dollars, established new institutions, and expanded the ecosystem. Experts cited in the report said the country now has world-class infrastructure, strong policy support, and an integrated system that compares well regionally, even if global recognition has not caught up with the capabilities built on the ground.

That gap between infrastructure and visibility remains central to the sector’s story. One expert from the National University of Singapore（NUS） described it as a “size and branding” issue, arguing that Singapore needs greater international visibility for its clinical-trial, research, and translation capabilities. The numbers show why the sector matters, even if it is not yet dominant. 

In 2023, the biomedical industry accounted for 2.6 percent of Singapore’s gross domestic product, employed 26,481 people, and manufactured almost S$38 billion worth of products for the global market. More than 80 leading biomedical companies have regional headquarters there. Output from biopharmaceutical manufacturing reached S$18.7 billion in 2023, while the medical technology sector now employs more than 16,900 workers across over 400 enterprises. Those figures suggest depth and staying power, but the report indicates that international branding and market-facing success still trail the country’s research credentials.

Drug Approvals and Startup Growth Signal Momentum, but Commercialization Remains Uneven

The report highlights several developments that suggest progress is no longer merely theoretical. In addition to Vonjo, Singapore-based work has contributed to Crovalimab, an antibody treatment developed by Chugai in Singapore for a rare and life-threatening blood disorder; the treatment received FDA approval last year. 

In 2022, the Experimental Drug Development Centre（EDDC）, set up by A*STAR in 2019, reached a global licensing agreement that gave Boehringer Ingelheim exclusive worldwide rights to research, develop, and commercialize products based on tumor-specific antibodies from A*STAR. Separately, Chugai Pharmabody Research worked with A*STAR on an anti-dengue antibody called AID351, and in January this year, GSK signed a deal to evaluate potential funding for clinical studies of the treatment. These are meaningful markers of translational progress.

Even so, the report makes clear that commercialization remains the sector’s hardest test. Former EDB chairman Philip Yeo said Singapore has been good at scientific discovery, but less successful at bringing innovations to market. Venture funding has improved, with at least seven Singapore biotech companies raising S$100 million or more since 2020; before that, only TauRx Pharmaceuticals had crossed that threshold. 

The EDB also said startups in biotech, medtech, and digital health closed more than 30 deals in 2023, totaling over US$600 million through fundraising, licensing, and development partnerships. Yet investors and entrepreneurs cited in the report said many startups still lack experienced commercial mentoring, especially from globally sophisticated venture capital firms able to shape products for market demand from early stages. In that sense, the sector is no longer short of science alone; it is still working to build the business systems that convert science into durable, scaled enterprises.

A Stronger Ecosystem Faces Job Pressures, Capital Gaps, and the Need for Global Reach

The report also points to a more complicated picture for graduates and early-career professionals. Data from the 2024 Joint Autonomous Universities Graduate Employment Survey, published on Feb. 24, showed that graduates in the sciences cluster earned a median monthly salary of S$4,125 within six months of their final exams, below the overall average of S$4,500 across all courses. Their full-time permanent employment rate was 72.3 percent, also below the overall average of 79.5 percent. 

Accounts from graduates suggest improvement over the past two decades, but not a consistently easy market. One recent NUS life sciences graduate told the outlet that job listings could attract more than 100 applicants within hours, while some classmates remained unemployed a year after graduation or switched into other sectors. At the same time, industry and university leaders said opportunities have expanded as more biotech firms, multinational drugmakers, public research institutions, and startups have entered the ecosystem.

Looking ahead, experts in the report said the next stage depends less on building laboratories and more on strengthening late-stage drug development, overseas business networks, and risk-tolerant capital. OCBC Bank said the biomedical cluster remains modest compared with finance, technology, and trade, and that commercialization is constrained by Singapore’s small domestic market and the long timelines required for drug development. 

Others argued that the country needs more outward-looking partnerships with overseas investors and more support for regional export strategies, regulatory alignment, and late-stage clinical trials. Several future-facing areas were identified as possible niches, including data-driven research through the National Precision Medicine Programme, nucleic acid therapeutics, cell therapies, and potentially a more advanced regulatory approach for products developed locally. 

For now, the sector stands as both a policy achievement and an unfinished project: a place with robust infrastructure, growing startup activity, and a handful of high-profile biomedical wins, but also one still trying to turn scientific capability into broader commercial and workforce impact.

Reference:
https://www.channelnewsasia.com/today/big-read/singapore-biomedical-sector-progress-challenges-5141161

Author

Oscar Wu

Fostering knowledge sharing to create a more fluid and transparent information landscape.